HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

arcyriaflavin A

from marine ascidian, Eudistoma sp.; structure given in first source

Also Known As:

12,13-dihydro-5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione monohydrate

Networked: 5 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Carbazoles: 32
        arcyriaflavin A: 5
  - 3-Ring Heterocyclic Compounds
    - Carbazoles: 32
      - arcyriaflavin A: 5

Experts

1.	Fu, Lu: 1 article (01/2021)
2.	Qin, Jiangjiang: 1 article (01/2021)
3.	Tian, Saisai: 1 article (01/2021)
4.	Xu, Jia: 1 article (01/2021)
5.	Yuan, Li: 1 article (01/2021)
6.	Zhang, Jinbo: 1 article (01/2021)
7.	Zhang, Weidong: 1 article (01/2021)
8.	Chilczuk, Tomasz: 1 article (01/2020)
9.	El Omari, Mustafa: 1 article (01/2020)
10.	Enke, Heike: 1 article (01/2020)

Related Diseases

1.	Endometriosis 07/18/2017 - "This is the first study to demonstrate the potential usefulness of arcyriaflavin A as a therapeutic agent for endometriosis. " 07/18/2017 - "Arcyriaflavin a, a cyclin D1-cyclin-dependent kinase4 inhibitor, induces apoptosis and inhibits proliferation of human endometriotic stromal cells: a potential therapeutic agent in endometriosis." 07/18/2017 - "This study aimed to determine whether arcyriaflavin A, a representative inhibitor of cyclin D1-cyclin-dependent kinase 4 (CDK4), is beneficial in the treatment of endometriosis. "
2.	Neoplasms (Cancer) 01/01/2020 - "As the isolated tjipanazoles show structural similarity to arcyriaflavin A, an inhibitor of the clinically relevant multidrug-transporter ABCG2 overexpressed by different cancer cell lines, the isolated compounds were tested for ABCG2 inhibitory activity. " 01/01/2023 - "The present application reports a series of novel Arcyriaflavin-A derivatives as PIM kinase inhibitors for the effective treatment of cancer. " 01/01/2023 - "Novel Arcyriaflavin-A Derivatives as PIM Kinase Inhibitors for Treating Cancer."
3.	Glioblastoma (Glioblastoma Multiforme) 11/17/2022 - "Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells."
4.	Breast Neoplasms (Breast Cancer) 01/01/2021 - "Furthermore, a in silico screening of druggable targets and compounds from CTRP and PRISM databases was performed, resulting in the identification of five target genes (HMMR, CCNB1, CDC25C, AURKA, and CENPE) and five agents (oligomycin A, panobinostat, (+)-JQ1, voxtalisib, and arcyriaflavin A), which might have therapeutic potential in treating high-risk breast cancer patients. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Cyclins
3.	Aurora Kinase A
4.	Panobinostat
5.	XL765
6.	oligomycin A
7.	berbamine (penduline)